Gerald H. Clamon

6.9k total citations · 1 hit paper
115 papers, 4.7k citations indexed

About

Gerald H. Clamon is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Gerald H. Clamon has authored 115 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 53 papers in Pulmonary and Respiratory Medicine and 22 papers in Molecular Biology. Recurrent topics in Gerald H. Clamon's work include Lung Cancer Treatments and Mutations (31 papers), Lung Cancer Research Studies (28 papers) and Lung Cancer Diagnosis and Treatment (17 papers). Gerald H. Clamon is often cited by papers focused on Lung Cancer Treatments and Mutations (31 papers), Lung Cancer Research Studies (28 papers) and Lung Cancer Diagnosis and Treatment (17 papers). Gerald H. Clamon collaborates with scholars based in United States, Canada and India. Gerald H. Clamon's co-authors include Roger G. Kathol, C. Le Péchoux, Jean‐Pierre Pignon, R. Arriagada, Walter J. Curran, P. Fournel, Kiyoyuki Furuse, Lesley Stewart, James E. Herndon and Anne Aupérin and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Gerald H. Clamon

113 papers receiving 4.5k citations

Hit Papers

Meta-Analysis of Concomitant Versus Sequential Radiochemo... 2010 2026 2015 2020 2010 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
    2010 1.3k citations Anne Aupérin, C. Le Péchoux et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gerald H. Clamon United States 30 2.6k 1.9k 661 554 518 115 4.7k
James A. Mailliard United States 38 1.8k 0.7× 3.8k 2.0× 772 1.2× 408 0.7× 825 1.6× 92 6.8k
Randolph S. Marks United States 41 2.8k 1.1× 2.7k 1.4× 1.4k 2.2× 569 1.0× 446 0.9× 121 5.9k
Jacqueline P. Williams United States 42 2.3k 0.9× 750 0.4× 1.1k 1.7× 2.6k 4.7× 626 1.2× 115 5.5k
Katherine M.W. Pisters United States 32 3.2k 1.3× 2.2k 1.1× 581 0.9× 539 1.0× 433 0.8× 80 4.7k
Philip J. Stella United States 39 2.1k 0.8× 3.3k 1.7× 1.0k 1.5× 258 0.5× 470 0.9× 126 5.6k
Karleen Schulze Canada 25 705 0.3× 782 0.4× 150 0.2× 394 0.7× 530 1.0× 49 2.6k
Masaru Narabayashi Japan 28 881 0.3× 1.0k 0.5× 338 0.5× 502 0.9× 278 0.5× 96 2.6k
Qiuling Shi China 34 962 0.4× 1.8k 0.9× 610 0.9× 138 0.2× 628 1.2× 248 4.1k
Johannes M.G. Bonfrèr Netherlands 33 994 0.4× 1.4k 0.7× 1.1k 1.7× 235 0.4× 467 0.9× 67 4.1k
Joanne Mortimer United States 47 3.0k 1.2× 4.4k 2.3× 1.4k 2.1× 1.6k 3.0× 2.0k 3.8× 260 9.5k

Countries citing papers authored by Gerald H. Clamon

Since Specialization
Citations

This map shows the geographic impact of Gerald H. Clamon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald H. Clamon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald H. Clamon more than expected).

Fields of papers citing papers by Gerald H. Clamon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald H. Clamon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald H. Clamon. The network helps show where Gerald H. Clamon may publish in the future.

Co-authorship network of co-authors of Gerald H. Clamon

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald H. Clamon. A scholar is included among the top collaborators of Gerald H. Clamon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald H. Clamon. Gerald H. Clamon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Furqan, Muhammad, Jun Zhang, Gerald H. Clamon, & Taher Abu Hejleh. (2018). P2.12-02 Phase II Study of Combination of Nab-Paclitaxel and Gemcitabine for Relapsed Small Cell Lung Cancer (SCLC). Journal of Thoracic Oncology. 13(10). S791–S791. 1 indexed citations
2.
Plichta, Kristin A., Muhammad Furqan, Taher Abu Hejleh, et al.. (2017). SBRT to adrenal metastases provides high local control with minimal toxicity. Advances in Radiation Oncology. 2(4). 581–587. 30 indexed citations
3.
Aupérin, Anne, C. Le Péchoux, Estelle Rolland, et al.. (2010). Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 28(13). 2181–2190. 1329 indexed citations breakdown →
4.
Karp, Daniel D., Seung‐Jae Lee, David H. Johnson, et al.. (2010). A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28(15_suppl). CRA7004–CRA7004. 9 indexed citations
5.
Rolland, Estelle, C. Le Péchoux, W.J. Curran, et al.. (2007). Concomitant Radio-chemotherapy (CT-RT) versus Sequential CT-RT In Locally Advanced Non-Small-Cell Lung Cancer (NSCLC): A Meta-Analysis Using Individual Patient Data (IPD) From Randomised Clinical Trials (RCTs). International Journal of Radiation Oncology*Biology*Physics. 69(3). S5–S5. 6 indexed citations
6.
7.
Yao, Min, Thanh Xuân Nguyễn, John M. Buatti, et al.. (2006). Changing Failure Patterns in Oropharyngeal Squamous Cell Carcinoma Treated With Intensity Modulated Radiotherapy and Implications for Future Research. American Journal of Clinical Oncology. 29(6). 606–612. 45 indexed citations
8.
Lima, Caio Max S. Rocha, James E. Herndon, Michael P. Kosty, Gerald H. Clamon, & Mark R. Green. (2001). Therapy choices among older patients with lung carcinoma. Cancer. 94(1). 181–187. 118 indexed citations
9.
10.
11.
Antman, Karen H., John Crowley, S P Balcerzak, et al.. (1998). A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.. PubMed. 82(7). 1288–95. 25 indexed citations
12.
Luikart, Sharon D., James E. Herndon, Donna Hollis, et al.. (1997). Phase I Trial of Etoposide, Carboplatin, and GM-CSF in Extensive Small-Cell Lung Cancer. American Journal of Clinical Oncology. 20(1). 24–30. 3 indexed citations
13.
14.
Clamon, Gerald H., Charles E. Riggs, Robert Dreicer, & Raymond J. Hohl. (1995). Phase II trial of edatrexate in patients with metastatic colorectal cancer. Investigational New Drugs. 13(4). 359–361. 3 indexed citations
15.
Muscato, Joseph J., Constance Cirrincione, Gerald H. Clamon, et al.. (1995). Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study. Lung Cancer. 13(3). 285–294. 9 indexed citations
16.
Clamon, Gerald H., Walter L. Eaton, Julian Rosenman, et al.. (1994). A Feasibility Study of Extended Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Phase II Trial of Cancer and Leukemia Group B. Cancer Investigation. 12(3). 273–282. 20 indexed citations
17.
Follett, Kenneth A., Patrick W. Hitchon, John G. Piper, et al.. (1992). Response of intractable pain to continuous intrathecal morphine: a retrospective study. Pain. 49(1). 21–25. 83 indexed citations
18.
Wen, B‐Chen, et al.. (1992). Leptomeningeal carcinomatosis following craniofacial resection of an ethmoid tumor. Journal of Surgical Oncology. 49(4). 266–269. 6 indexed citations
19.
Clamon, Gerald H., et al.. (1987). Phase 2 Trial of Streptozotocin by Continuous Infusion for Metastatic Colorectal Carcinoma. PubMed. 4(1). 43–46. 2 indexed citations
20.
Feld, Ronald, Gerald H. Clamon, Ronald H. Blum, et al.. (1985). Short course prophylactic cranial irradiation for small cell lung cancer. American Journal of Clinical Oncology. 8(5). 371–376. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James A. Mailliard Breakdown of academic impact, for papers by Randolph S. Marks Breakdown of academic impact, for papers by Jacqueline P. Williams Breakdown of academic impact, for papers by Katherine M.W. Pisters Breakdown of academic impact, for papers by Philip J. Stella Breakdown of academic impact, for papers by Karleen Schulze Breakdown of academic impact, for papers by Masaru Narabayashi Breakdown of academic impact, for papers by Qiuling Shi Breakdown of academic impact, for papers by Johannes M.G. Bonfrèr Breakdown of academic impact, for papers by Joanne Mortimer
Rankless by CCL
2026